Cardiac Allograft Vasculopathy and Insulin Resistance-Hope for New Therapeutic Targets

Endocrinology and Metabolism Clinics of North America

Volumn 36, Issue 4, 2007, Pages 965-981

  Potena, Luciano ^a   Valantine, Hannah A ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIHYPERTENSIVE AGENT; AZATHIOPRINE; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EVEROLIMUS; EZETIMIBE; FLUINDOSTATIN; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PRAVASTATIN; PREDNISOLONE; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ANGIOCARDIOGRAPHY; CARDIAC ALLOGRAFT VASCULOPATHY; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE COURSE; DRUG EFFICACY; DRUG MEGADOSE; DYSLIPIDEMIA; GENETIC PREDISPOSITION; GLYCEMIC CONTROL; HEART GRAFT; HEART TRANSPLANTATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; METABOLIC SYNDROME X; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; TREATMENT OUTCOME;

CORONARY DISEASE; DIABETES MELLITUS; HEART TRANSPLANTATION; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; INSULIN RESISTANCE; TRANSPLANTATION, HOMOLOGOUS;

CHICKEN ANEMIA VIRUS;

EID: 35648939769     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2007.07.012     Document Type: Review

References (80)

1. Costanzo M., Naftel D., Pritzker M., et al. Heart transplant coronary artery disease detected by coronary angiography: a multiinstitutional study of preoperative donor and recipient risk factor. J Heart Lung Transplant 17 (1998) 744-753
2. Billingham M. Hystopathology of graft coronary disease. J Heart Lung Transplant 11 (1992) S38-S44
3. Taylor D.O., Edwards L.B., Boucek M.M., et al. Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult heart transplantation report-2006. J Heart Lung Transplant 25 8 (2006) 869-879
4. Valantine H.A. Cardiac allograft vasculopathy: central role of endothelial injury leading to transplant "atheroma". Transplantation 76 6 (2003) 891-899
5. Mehra M. Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy. Am J Transplant 6 6 (2006) 1248-1256
6. Valantine H.A., and Schroeder J.S. Recent advances in cardiac transplantation. N Engl J Med 333 10 (1995) 660-661
7. Tufveson G., and Johnsson C. Chronic allograft dysfunction-chronic rejection revisited. Transplantation 70 3 (2000) 411-412
8. Blakolmer K., Jain A., Ruppert K., et al. Chronic liver allograft rejection in a population treated primarily with tacrolimus as baseline immunosuppression: long-term follow-up and evaluation of features for histopathological staging. Transplantation 69 11 (2000) 2330-2336
9. Girgis R.E., Tu I., Berry G.J., et al. Risk factors for the development of obliterative bronchiolitis after lung transplantation. J Heart Lung Transplant 15 12 (1996) 1200-1208
10. Liu G., and Butany J. Morphology of graft arteriosclerosis in cardiac transplant recipients. Hum Pathol 23 7 (1992) 768-773
11. Oni A.A., Ray J., and Hosenpud J.D. Coronary venous intimal thickening in explanted cardiac allografts. Evidence demonstrating that transplant coronary artery disease is a manifestation of a diffuse allograft vasculopathy. Transplantation 53 6 (1992) 1247-1251
12. Higuchi M.L., Benvenuti L.A., Demarchi L.M., et al. Histological evidence of concomitant intramyocardial and epicardial vasculitis in necropsied heart allografts: a possible relationship with graft coronary arteriosclerosis. Transplantation 67 12 (1999) 1569-1576
13. Russell M.E., Fujita M., Masek M.A., et al. Cardiac graft vascular disease. Nonselective involvement of large and small vessels. Transplantation 56 6 (1993) 1599-1601
14. Rose E.A., Smith C.R., Petrossian G.A., et al. Humoral immune responses after cardiac transplantation: correlation with fatal rejection and graft atherosclerosis. Surgery 106 2 (1989) 203-207 [discussion: 207-8]
15. Hauptman P.J., Nakagawa T., Tanaka H., et al. Acute rejection: culprit or coincidence in the pathogenesis of cardiac graft vascular disease?. J Heart Lung Transplant 14 6 Pt 2 (1995) S173-S180
16. Caforio A.L., Tona F., Fortina A.B., et al. Immune and nonimmune predictors of cardiac allograft vasculopathy onset and severity: multivariate risk factor analysis and role of immunosuppression. Am J Transplant 4 6 (2004) 962-970
17. Gao S.Z., Schroeder J.S., Hunt S.A., et al. Influence of graft rejection on incidence of accelerated graft coronary artery disease: a new approach to analysis. J Heart Lung Transplant 12 6 Pt 1 (1993) 1029-1035
18. Costanzo M.R. The role of histoincompatibility in cardiac allograft vasculopathy. J Heart Lung Transplant 14 6 Pt 2 (1995) S180-S184
19. Yeni-Komshian H., Carantoni M., Abbasi F., et al. Relationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy nondiabetic volunteers. Diabetes Care 23 2 (2000) 171-175
20. Facchini F., Chen Y.D., Hollenbeck C.B., et al. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 266 21 (1991) 3008-3011
21. Castelli W. Lipoproteins and cardiovascular disease: biological basis and epidemiological studies. Value Health 1 2 (1998) 105-109
22. Saadeh S., and Younossi Z.M. The spectrum of nonalcoholic fatty liver disease: from steatosis to nonalcoholic steatohepatitis. Cleve Clin J Med 67 2 (2000) 96-97 101-4
23. Despres J.P., Lamarche B., Mauriege P., et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 334 15 (1996) 952-957
24. Zavaroni I., Bonini L., Gasparini P., et al. Hyperinsulinemia in a normal population as a predictor of non-insulin-dependent diabetes mellitus, hypertension, and coronary heart disease: the Barilla factory revisited. Metabolism 48 8 (1999) 989-994
25. Facchini F., and Reaven G. Resistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease. J Clin Endocrinol Metab 83 (1998) 2773-2776
26. Valantine H., Rickenbacker P., Kemna M., et al. Metabolic abnormalities characteristic of dysmetabolic syndrome predict the development of transplant coronary artery disease: a prospective study. Circulation 2001 103 17 (2001) 2144-2152
27. Kemna M.S., Valantine H.A., Hunt S.A., et al. Metabolic risk factors for atherosclerosis in heart transplant recipients. Am Heart J 128 1 (1994) 68-72
28. Cantin B., Zhu D., Wen P., et al. Reversal of diabetes-induced rat graft transplant coronary artery disease by metformin. J Heart Lung Transplant 21 6 (2002) 637-643
29. de Lorgeril M., Dureau G., Boissonnat P., et al. Platelet function and composition in heart transplant recipients compared with nontransplanted coronary patients. Arterioscler Thromb 12 2 (1992) 222-230
30. Keogh A. Calcineurin inhibitors in heart transplantation. J Heart Lung Transplant 23 5 Suppl (2004) S202-S206
31. Jindal R.M., Sidner R.A., and Milgrom M.L. Post-transplant diabetes mellitus. The role of immunosuppression. Drug Saf 16 4 (1997) 242-257
32. Grassi G., Dell'Oro R., Quarti-Trevano F., et al. Neuroadrenergic and reflex abnormalities in patients with metabolic syndrome. Diabetologia 48 7 (2005) 1359-1365
33. Rickenbacher P.R., Kemna M.S., Pinto F.J., et al. Coronary artery intimal thickening in the transplanted heart. An in vivo intracoronary ultrasound study of immunologic and metabolic risk factors. Transplantation 61 1 (1996) 46-53
34. de Vries A.P., Bakker S.J., van Son W.J., et al. Insulin resistance as putative cause of chronic renal transplant dysfunction. Am J Kidney Dis 41 4 (2003) 859-867
35. Wenke K., Meiser B., Thiery J., et al. Simvastatin reduces graft vessel disease and morality after heart transplantation. Circulation 96 (1997) 1398-1402
36. White M., Ross H., Haddad H., et al. Subclinical inflammation and prothrombotic state in heart transplant recipients: impact of cyclosporin microemulsion vs. tacrolimus. Transplantation 82 6 (2006) 763-770
37. McLaughlin T., Abbasi F., Cheal K., et al. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med 139 (2003) 802-809
38. Biadi O., Potena L., Fearon W.F., et al. Interplay between systemic inflammation and markers of insulin resistance in cardiovascular prognosis after heart transplantation. J Heart Lung Transplant 26 4 (2007) 324-330
39. Ferre' P. The biology of peroxisome proliferator-activated receptors. Relationship with lipid metabolism and insulin sensitivity. Diabetes 53 Suppl 1 (2004) S43-S50
40. Schupp M., Janke J., Clasen R., et al. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor gamma activity. Circulation 109 (2004) 2054-2057
41. Yousufuddin M., Haji S., Starling R., et al. Cardiac angiotensin II receptors as predictors of transplant coronary artery disease following heart transplantation. Eur Heart J 25 (2004) 377-385
42. Kosuge H., Haraguchi G., Koga N., et al. Pioglitazone prevents acute and chronic cardiac allograft rejection. Circulation 113 (2006) 2613-2622
43. Pethig K., Klauss V., Heublein B., et al. Progression of cardiac allograft vascular disease as assessed by serial intravascular ultrasound: correlation to immunological and non-immunological risk factors. Heart 84 5 (2000) 494-498
44. Kapadia S., Nissen S., Ziada K., et al. Impact of lipid abnormalities in development and progression of transplant coronary disease: a serial intravascular ultrasound study. J Am Coll Cardiol 38 (2001) 206-213
45. Potena L., Grigioni F., Ortolani P., et al. Relevance of cytomegalovirus infection and coronary-artery remodeling in the first year after heart transplantation: a prospective three-dimensional intravascular ultrasound study. Transplantation 75 6 (2003) 839-843
46. Kobashigawa J., Starling R., Mehra M., et al. Multicenter retrospective analysis of cardiovascular risk factors affecting long-term outcome of de novo cardiac transplant recipients. J Heart Lung Transplant 25 (2006) 1063-1069
47. Zawaideh M.A., Ghishan F.K., and Molmenti E.P. Regulation of cholesterol homeostasis in solid organ transplantation. Transplantation 81 3 (2006) 316-317
48. Lindenfeld J., Miller G., Shakar S., et al. Drug therapy in the heart transplant recipient. Part II: immunosuppressive drugs. Circulation 110 25 (2004) 3858-3865
49. Taylor D., Barr M., Radovancevic B., et al. A randomized multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Transplant 18 (1999) 336-345
50. Eisen H.J., Tuzcu E.M., Dorent R., et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 349 9 (2003) 847-858
51. Keogh A., Richardson M., Ruygrok P., et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation 110 17 (2004) 2694-2700
52. Kobashigawa J.A., Katznelson S., Laks H., et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 333 10 (1995) 621-627
53. Wu H., Ballantyne C., Short B., et al. Statin use and risks of death or fatal rejection in the heart transplant lipid registry. Am J Cardiol 95 (2004) 367-372
54. Grigioni F., Carigi S., Potena L., et al. Long-term safety and effectiveness of statins for heart transplant recipients in routine clinical practice. Transplant Proc 38 5 (2006) 1507-1510
55. Holdaas H., Fellstrom B., Cole E., et al. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transplant 5 12 (2005) 2929-2936
56. Patel A.R., Ambrose M.S., Duffy G.A., et al. Treatment of hypercholesterolemia with ezetimibe in cardiac transplant recipients. J Heart Lung Transplant 26 3 (2007) 281-284
57. Radovancevic B., Poindexter S., Birovijev S., et al. Risk factors for development of accelerated coronary artery disease in cardiac transplant recipients. Eur J Cardiothorac Surg 4 (1990) 309-313
58. Ciarka A., Najem B., Cuylits N., et al. Effects of peripheral chemoreceptors deactivation on sympathetic activity in heart transplant recipients. Hypertension 45 5 (2005) 894-900
59. Klauss V., Koning A., Spes C., et al. Cyclosporine versus tacrolimus (FK 506) for prevention of cardiac allograft vasculopathy. Am J Cardiol 85 (2000) 266-269
60. Grimm M., Rinaldi M., Yonan N.A., et al. Superior prevention of acute rejection by tacrolimus vs. cyclosporine in heart transplant recipients-a large European trial. Am J Transplant 6 6 (2006) 1387-1397
61. Braith R.W., Mills R.M., Wilcox C.S., et al. High-dose angiotensin-converting enzyme inhibition restores body fluid homeostasis in heart-transplant recipients. J Am Coll Cardiol 41 3 (2003) 426-432
62. Schroeder J.S., Gao S.Z., Alderman E.L., et al. A preliminary study of diltiazem in the prevention of coronary artery disease in heart-transplant recipients. N Engl J Med 328 3 (1993) 164-170
63. Mehra M.R., Ventura H.O., Smart F.W., et al. An intravascular ultrasound study of the influence of angiotensin-converting enzyme inhibitors and calcium entry blockers on the development of cardiac allograft vasculopathy. Am J Cardiol 75 12 (1995) 853-854
64. Bae J.H., Rihal C.S., Edwards B.S., et al. Association of angiotensin-converting enzyme inhibitors and serum lipids with plaque regression in cardiac allograft vasculopathy. Transplantation 82 8 (2006) 1108-1111
65. Erinc K., Yamani M.H., Starling R.C., et al. The effect of combined angiotensin-converting enzyme inhibition and calcium antagonism on allograft coronary vasculopathy validated by intravascular ultrasound. J Heart Lung Transplant 24 8 (2005) 1033-1038
66. Nieuwenhuis M.G., and Kirkels J.H. Predictability and other aspects of post-transplant diabetes mellitus in heart transplant recipients. J Heart Lung Transplant 20 7 (2001) 703-708
67. Hathout E.H., Chinnock R.E., Johnston J.K., et al. Pediatric post-transplant diabetes: data from a large cohort of pediatric heart-transplant recipients. Am J Transplant 3 8 (2003) 994-998
68. Depczynski B., Daly B., Campbell L.V., et al. Predicting the occurrence of diabetes mellitus in recipients of heart transplants. Diabet Med 17 1 (2000) 15-19
69. Kahn J., Rehak P., Schweiger M., et al. The impact of overweight on the development of diabetes after heart transplantation. Clin Transplant 20 1 (2006) 62-66
70. Hjelmesaeth J., Sagedal S., Hartmann A., et al. Asymptomatic cytomegalovirus infection is associated with increased risk of new-onset diabetes mellitus and impaired insulin release after renal transplantation. Diabetologia 47 9 (2004) 1550-1556
71. Gunnarsson R., Lundgren G., Magnusson G., et al. Steroid diabetes-a sign of overtreatment with steroids in the renal graft recipient?. Scand J Urol Nephrol Suppl 54 (1980) 135-138
72. Wilkinson A., Davidson J., Dotta F., et al. Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin Transplant 19 3 (2005) 291-298
73. Heisel O., Heisel R., Balshaw R., et al. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant 4 4 (2004) 583-595
74. Kobashigawa J.A., Miller L.W., Russell S.D., et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant 6 6 (2006) 1377-1386
75. Kato T., Chan M.C., Gao S.Z., et al. Glucose intolerance, as reflected by hemoglobin A1c level, is associated with the incidence and severity of transplant coronary artery disease. J Am Coll Cardiol 43 6 (2004) 1034-1041
76. Russo M.J., Chen J.M., Hong K.N., et al. Survival after heart transplantation is not diminished among recipients with uncomplicated diabetes mellitus: an analysis of the United Network of Organ Sharing database. Circulation 114 21 (2006) 2280-2287
77. Klingenberg R., Gleissner C., Koch A., et al. Impact of pre-operative diabetes mellitus upon early and late survival after heart transplantation: a possible era effect. J Heart Lung Transplant 24 9 (2005) 1239-1246
78. Lemieux I., Houde I., Pascot A., et al. Effects of prednisone withdrawal on the new metabolic triad in cyclosporine-treated kidney transplant patients. Kidney Int 62 5 (2002) 1839-1847
79. Erdmann E., Dormandy J.A., Charbonnel B., et al. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 49 17 (2007) 1772-1780
80. Senechal M., Lemieux I., Beucler I., et al. Features of the metabolic syndrome of "hypertriglyceridemic waist" and transplant coronary artery disease. J Heart Lung Transplant 24 7 (2005) 819-826